The inventor of CRISPR gene-editing technology is pushing back against the widespread belief that artificial intelligence will soon replace human scientists in drug discovery. Jennifer Doudna, a biochemistry professor at UC Berkeley and 2020 Nobel Prize winner, expressed skepticism about whether AI systems like ChatGPT can actually generate novel medical breakthroughs, even as pharmaceutical companies are racing to sign licensing agreements with AI firms.

What's Driving the AI Hype in Drug Development?

Pharmaceutical companies are betting heavily on AI to accelerate drug development. Major licensing deals between pharma and AI companies have multiplied in recent years, with executives making bold promises about the technology's potential. Anthropic's Chief Executive Officer Dario Amodei has claimed that AI will eventually help eliminate "most cancer" by making it easier to tailor treatments to a patient's DNA. These optimistic projections have created momentum in the industry, with investors and executives viewing AI as a transformative force in medicine.

However, Doudna's perspective offers a sobering counterpoint to this enthusiasm. In an interview with Bloomberg's "The Circuit with Emily Chang," she directly challenged the narrative that AI chatbots are on the verge of making major discoveries. "I think that innovation is still really in the domain of human beings right now," Doudna said. "I'm not seeing chatbots coming up with a brand new idea".

"I think that innovation is still really in the domain of human beings right now. I'm not seeing chatbots coming up with a brand new idea," said Jennifer Doudna.

Jennifer Doudna, Professor of Biochemistry at UC Berkeley and 2020 Nobel Prize Winner

Why Does Doudna's Skepticism Matter?

Doudna's caution carries particular weight because she helped invent one of the most transformative biotechnologies of the past decade. CRISPR-Cas9, introduced in 2012, fundamentally changed how scientists approach genetic engineering by allowing researchers to precisely edit DNA sequences. The technology earned her the Nobel Prize in Chemistry in 2020, making her one of the most credible voices in biotech innovation.

Her skepticism about AI's role in drug discovery doesn't mean she dismisses the technology entirely. Rather, she appears concerned that the industry is overstating AI's current capabilities and underestimating the complexity of genuine scientific innovation. The distinction matters because it shapes how companies allocate research funding and how investors evaluate biotech opportunities.

What Are the Real Limitations of Current Gene-Editing Technology?

While Doudna remains optimistic about CRISPR's future, she acknowledges significant practical hurdles that AI alone cannot solve. The gene-editing process itself remains "quite involved," and the most common current applications are expensive and can be unpleasant for patients. Additionally, CRISPR sometimes edits the wrong gene sequence or fails to locate the target gene altogether.

These limitations highlight why human expertise remains essential. Scientists must understand not just the technical mechanics of gene editing, but also the biological context, potential side effects, and patient-specific factors that influence treatment outcomes. Doudna noted that designing genetic changes is far more complicated than popular culture suggests, involving multiple genes and environmental factors that are difficult to predict or control.

How Are Scientists Advancing Gene-Editing Capabilities?

Despite current limitations, progress is accelerating. Earlier in June 2026, scientists at Columbia University developed a new method to edit DNA more precisely, according to reporting by the New York Times. Additionally, the U.S. Food and Drug Administration approved the first gene therapy using CRISPR in December 2023 for patients with sickle cell disease, demonstrating that the technology is moving from laboratory research into real-world medical applications.

• Columbia University Breakthrough: Researchers developed a more precise DNA editing method to overcome current accuracy limitations in CRISPR technology.
• FDA Approval Milestone: The first CRISPR-based gene therapy was approved in December 2023 for treating sickle cell disease in patients.
• Rare Disease Focus: Doudna expressed particular enthusiasm about CRISPR's potential to treat patients with rare genetic diseases where traditional therapies have failed.

"I feel very excited about where it's headed, the opportunities to treat people that have rare disease," said Doudna.

Jennifer Doudna, Professor of Biochemistry at UC Berkeley

What's at Stake for U.S. Scientific Leadership?

Beyond the AI debate, Doudna raised concerns about a broader threat to American scientific innovation. The Trump Administration has terminated numerous federal grants from the National Institutes of Health (NIH), creating uncertainty about the future of medical research funding in the United States. This funding crisis could have long-term consequences for the nation's competitive position in global science.

Doudna emphasized the economic importance of sustained research investment. "Every dollar that's been invested from the NIH in research leads to about $2.50 of economic benefit," she noted. "If we don't continue our investment in science, others will". This statement underscores a critical point: the debate over AI's role in drug discovery occurs against a backdrop of shrinking public research funding, which could limit the human expertise and infrastructure that AI tools depend on.

Doudna

The tension between AI enthusiasm and scientific reality reflects a broader challenge facing the biotech industry. While artificial intelligence can accelerate certain aspects of drug development, such as screening molecular compounds or analyzing genetic data, the fundamental work of scientific innovation appears to require human creativity, intuition, and domain expertise. Doudna's skepticism suggests that companies betting their futures on AI-driven drug discovery may need to recalibrate their expectations and continue investing in the human scientists who ultimately drive breakthroughs.